Literature DB >> 29033317

Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.

Daniel R Gentile1, Manoj K Rathinaswamy2, Meredith L Jenkins2, Steven M Moss1, Braden D Siempelkamp2, Adam R Renslo3, John E Burke4, Kevan M Shokat5.   

Abstract

Covalent inhibitors of K-Ras(G12C) have been reported that exclusively recognize the GDP state. Here, we utilize disulfide tethering of a non-natural cysteine (K-Ras(M72C)) to identify a new switch-II pocket (S-IIP) binding ligand (2C07) that engages the active GTP state. Co-crystal structures of 2C07 bound to H-Ras(M72C) reveal binding in a cryptic groove we term S-IIG. In the GppNHp state, 2C07 binding to a modified S-IIP pushes switch I away from the nucleotide, breaking the network of polar contacts essential for adopting the canonical GTP state. Biochemical studies show that 2C07 alters nucleotide preference and inhibits SOS binding and catalyzed nucleotide exchange. 2C07 was converted to irreversible covalent analogs, which target both nucleotide states, inhibit PI3K activation in vitro, and function as occupancy probes to detect reversible engagement in competition assays. Targeting both nucleotide states opens the possibility of inhibiting oncogenic mutants of Ras, which exist predominantly in the GTP state in cells.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GTPase; Ras; crystallography; drug discovery; hydrogen-deuterium exchange mass spectrometry; inhibitor; switch-II pocket

Mesh:

Substances:

Year:  2017        PMID: 29033317      PMCID: PMC5915340          DOI: 10.1016/j.chembiol.2017.08.025

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  53 in total

1.  NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation.

Authors:  Roopa Thapar; Jason G Williams; Sharon L Campbell
Journal:  J Mol Biol       Date:  2004-11-05       Impact factor: 5.469

2.  Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants.

Authors:  Shin Muraoka; Fumi Shima; Mitsugu Araki; Tomoko Inoue; Akiko Yoshimoto; Yuichi Ijiri; Nobuaki Seki; Atsuo Tamura; Takashi Kumasaka; Masaki Yamamoto; Tohru Kataoka
Journal:  FEBS Lett       Date:  2012-05-11       Impact factor: 4.124

3.  Fundamental link between folding states and functional states of proteins.

Authors:  Hans Robert Kalbitzer; Michael Spoerner; Petra Ganser; Constantin Hozsa; Werner Kremer
Journal:  J Am Chem Soc       Date:  2009-11-25       Impact factor: 15.419

4.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Authors:  John C Hunter; Anuj Manandhar; Martin A Carrasco; Deepak Gurbani; Sudershan Gondi; Kenneth D Westover
Journal:  Mol Cancer Res       Date:  2015-06-02       Impact factor: 5.852

5.  Guanosine triphosphatase stimulation of oncogenic Ras mutants.

Authors:  M R Ahmadian; T Zor; D Vogt; W Kabsch; Z Selinger; A Wittinghofer; K Scheffzek
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM.

Authors:  T Geoff G Battye; Luke Kontogiannis; Owen Johnson; Harold R Powell; Andrew G W Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

7.  Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.

Authors:  Braden D Siempelkamp; Manoj K Rathinaswamy; Meredith L Jenkins; John E Burke
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

8.  Site-directed mutagenesis by combination of homologous recombination and DpnI digestion of the plasmid template in Escherichia coli.

Authors:  Jing Li; Chunhua Li; Wei Xiao; Dongxia Yuan; Gang Wan; Lixin Ma
Journal:  Anal Biochem       Date:  2007-10-30       Impact factor: 3.365

Review 9.  Scaling and assessment of data quality.

Authors:  Philip Evans
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2005-12-14

10.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13
View more
  31 in total

Review 1.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 2.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

Review 3.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

4.  Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

Authors:  Aruna Wijeratne; Junpeng Xiao; Christopher Reutter; Kelly W Furness; Rebecca Leon; Mohammad Zia-Ebrahimi; Rachel N Cavitt; John M Strelow; Robert D Van Horn; Sheng-Bin Peng; David A Barda; Thomas A Engler; Michael J Chalmers
Journal:  ACS Med Chem Lett       Date:  2018-05-21       Impact factor: 4.345

Review 5.  Dynamic structural biology at the protein membrane interface.

Authors:  John E Burke
Journal:  J Biol Chem       Date:  2019-01-28       Impact factor: 5.157

Review 6.  KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Authors:  Misako Nagasaka; Yiwei Li; Ammar Sukari; Sai-Hong Ignatius Ou; Mohammed Najeeb Al-Hallak; Asfar S Azmi
Journal:  Cancer Treat Rev       Date:  2020-01-23       Impact factor: 12.111

7.  Structural basis of the atypical activation mechanism of KRASV14I.

Authors:  Asim K Bera; Jia Lu; Thomas E Wales; Sudershan Gondi; Deepak Gurbani; Andrew Nelson; John R Engen; Kenneth D Westover
Journal:  J Biol Chem       Date:  2019-07-24       Impact factor: 5.157

Review 8.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.

Authors:  Feixiong Cheng; Han Liang; Atul J Butte; Charis Eng; Ruth Nussinov
Journal:  Pharmacol Rev       Date:  2018-12-13       Impact factor: 25.468

Review 9.  Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Authors:  Imran Khan; J Matthew Rhett; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-10-31       Impact factor: 4.739

Review 10.  Pharmacological targeting of RAS: Recent success with direct inhibitors.

Authors:  John P O'Bryan
Journal:  Pharmacol Res       Date:  2018-10-23       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.